Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS 86 3-Year FCF Growth Rate is 78.60% as of Jun. 2026, which is 373% above its 10-year median of 16.60. GuruFocus rates ASX:VLS with a GF Score™ of 86/100 and a GF Value™ of A$2.63 (Fairly Valued). The stock has 6 warning signs investors should review. Among 658 Drug Manufacturers companies, Vita Life Sciences ranks better than 95.74% on this metric.
During the past 12 months, Vita Life Sciences's average Free Cash Flow per Share Growth Rate was 58.30% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 78.60% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 14.90% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 14.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Vita Life Sciences was 114.00% per year. The lowest was -18.40% per year. And the median was 16.60% per year.
Vita Life Sciences (ASX:VLS) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Vita Life Sciences 3-Year FCF Growth Rate Related Terms
ASX:VLS vs ZTS: 3-Year FCF Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences 3-Year FCF Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's 3-Year FCF Growth Rate falls into.
Vita Life Sciences 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 78.60% mean?
Vita Life Sciences (ASX:VLS) has a 3-Year FCF Growth Rate of 78.60% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Vita Life Sciences and its competitors. This is 373% above median its historical median of 16.60. According to the industry distribution chart, Vita Life Sciences ranks #28 out of 658 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Vita Life Sciences' 3-Year FCF Growth Rate too high?
Vita Life Sciences' current 3-Year FCF Growth Rate of 78.60% is 373% above median its 10-year median of 16.60. The Drug Manufacturers industry median 3-Year FCF Growth Rate is 8.95. Vita Life Sciences' value of 78.60% is 778.2% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #28 out of 658 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' 3-Year FCF Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #28 out of 658 companies for 3-Year FCF Growth Rate. This places Vita Life Sciences in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year FCF Growth Rate is 8.95. Vita Life Sciences' value of 78.60% is 778.2% above this benchmark. While the company's 10-year median is 16.60 vs. the industry median of 8.95, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Drug Manufacturers company?
The median 3-Year FCF Growth Rate among Drug Manufacturers companies is 8.95, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current 3-Year FCF Growth Rate of 78.60% is 778.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median 3-Year FCF Growth Rate is 8.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current 3-Year FCF Growth Rate is 78.60%, which is 373% above median its own 10-year median of 16.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.63, compared to a current price of A$2.79 — trading 6.1% above its estimated fair value. The current 3-Year FCF Growth Rate is 78.60%, which is 373% above median its 10-year median of 16.60 and 778.2% above the Drug Manufacturers industry median of 8.95. Vita Life Sciences' overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current 3-Year FCF Growth Rate is 78.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.79 is trading 6.1% above its estimated GF Value™ of A$2.63.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
3-Year FCF Growth Rate: 78.60% (373% above median its 10-year median of 16.60)
GF Value™: A$2.63 vs. price of A$2.79 (6.1% above fair value)
Industry Position: 778.2% above the Drug Manufacturers median (#28 of 658)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
86GF Score
Get the complete analysis for ASX:VLS
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
